A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
7actual
Sites
7
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Early discontinuation based on strategic sponsor decision not driven by any safety concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-13 | actual | When the study began enrolling |
| Primary completion | 2025-08-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-08 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Interventions
- Biological: SAR443579
- Drug: venetoclax — also filed as VENCLYXTO / VENCLEXTA
- Drug: azacitidine
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)/serious adverse events (SAEs)/adverse events of special interest (AESIs), laboratory abnormalities
measured Day 1 to 30 days after the last administration of study treatment
Substudy 01: Incidence of dose limiting toxicities (DLTs) (escalation part)
measured Day 1 to Day 28
Substudy 01: Complete Remission (CR) rate (optimization part)
measured Day 1 to 30 days after the last administration of study treatment
Substudy 01: Complete Remission (CR) rate (expansion part)
measured Day 1 up to 6 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed